H.R. 8205 · 119th Congress

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Introduced on Apr 6, 2026 by Mike Quigley (D-IL-5). 103 cosponsors, 39 of them from another party. Latest action (Sep 28, 2026): Passed Senate without amendment by Voice Vote. (consideration: CR S5120)

Stage
Passed both chambers
Introduced
Apr 6, 2026
Cosponsors
103
39 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. Passed one chamber
  4. Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.

Subjects

  • Department of Health and Human Services
  • Drug therapy
  • Food and Drug Administration (FDA)
  • Government information and archives
  • Health programs administration and funding
  • Internet, web applications, social media
  • Medical research
  • National Institutes of Health (NIH)
  • Neurological disorders
  • Public-private cooperation
  • Research administration and funding

Summary

By the Congressional Research Service (Reported to House, Jul 9, 2026). Public domain.

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The bill reauthorizes

  • grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
  • grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
  • a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.

Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.

Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Mike QuigleyD-IL-5Sponsor

Democrats · 64

Republicans · 39

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Apr 6, 2026Introduced in House
  2. Apr 6, 2026Introduced in House
  3. Apr 6, 2026 · HouseReferred to the House Committee on Energy and Commerce.
  4. Apr 6, 2026 · HouseReferred to the Subcommittee on Health.
  5. May 13, 2026 · HouseSubcommittee Consideration and Mark-up Session Held
  6. May 13, 2026 · HouseForwarded by Subcommittee to Full Committee by Voice Vote.
  7. May 21, 2026 · HouseCommittee Consideration and Mark-up Session Held
  8. May 21, 2026 · HouseOrdered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
  9. Jul 9, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
  10. Jul 9, 2026 · HouseReported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
  11. Jul 9, 2026 · HousePlaced on the Union Calendar, Calendar No. 637.
  12. Jul 20, 2026 · HouseMr. Guthrie moved to suspend the rules and pass the bill, as amended.
  13. Jul 20, 2026 · HouseConsidered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
  14. Jul 20, 2026 · HouseDEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
  15. Jul 20, 2026 · HouseAt the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
  16. Jul 22, 2026 · HouseConsidered as unfinished business. (consideration: CR H5159)
  17. Jul 22, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  18. Jul 22, 2026 · HouseOn motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  19. Jul 22, 2026 · HouseMotion to reconsider laid on the table Agreed to without objection.
  20. Jul 23, 2026 · SenateReceived in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
  21. Sep 28, 2026Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
  22. Sep 28, 2026 · SenatePassed Senate without amendment by Voice Vote. (consideration: CR S5120)

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. I AM ALS2 reports
    $60K reported (all issues)
  2. THE ALS ASSOCIATION2 reports
    $60K reported (all issues)
  3. Muscular Dystrophy Association, Inc.1 report
    $60K reported (all issues)Federal contractor: MUSCULAR DYSTROPHY ASSOCIATION INC$315K in contracts, FY2026AI match · 100%
  4. NRx Pharmaceuticals, Inc. (formerly known as NeuroRx)1 report
    $24K reported (all issues)

Reports filed in 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.